{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:08:12Z","timestamp":1779062892670,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>RNA-based therapies have been studied for decades, gaining global recognition with the success of the Pfizer-BioNTech mRNA vaccine. Despite ongoing challenges in standardization and optimization, RNA therapeutics have become central to precision medicine. This success has driven interest in oncology applications, particularly microRNAs (miRNAs), which regulate gene expression and cancer-related processes. This article reviews RNA-based cancer therapies, highlighting miRNA potential and clinical translation challenges.<\/jats:p>","DOI":"10.1038\/s41541-026-01425-9","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:16:59Z","timestamp":1774451819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer vaccines and RNA therapeutics: exploring the impact of microRNAs"],"prefix":"10.1038","volume":"11","author":[{"given":"Miriam Valeria","family":"Rojas-Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Mui\u00f1os-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Arriaga-Canon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alonso","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1425_CR1","first-page":"1","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. mRNA-based therapeutics: Powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 1\u201335 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1425_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1425_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","volume":"597","author":"E Dolgin","year":"2021","unstructured":"Dolgin, E. The tangled history of mRNA vaccines. Nature 597, 318\u2013324 (2021).","journal-title":"Nature"},{"key":"1425_CR4","doi-asserted-by":"publisher","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","volume":"28","author":"R Verbeke","year":"2019","unstructured":"Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. Three decades of messenger RNA vaccine development. Nano Today 28, 100766 (2019).","journal-title":"Nano Today"},{"key":"1425_CR5","first-page":"1397","volume":"55","author":"RM Conry","year":"1995","unstructured":"Conry, R. M. et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55, 1397\u20131400 (1995).","journal-title":"Cancer Res"},{"key":"1425_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1425_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).","journal-title":"Mol. Cancer"},{"key":"1425_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00644-3","volume":"12","author":"Y Gao","year":"2024","unstructured":"Gao, Y., Yang, L., Li, Z., Peng, X. & Li, H. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends. Biomark. Res. 12, 93 (2024).","journal-title":"Biomark. Res."},{"key":"1425_CR9","unstructured":"Rosenberg, S. A Phase I\/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer. https:\/\/clinicaltrials.gov\/study\/NCT03480152 (2020)."},{"key":"1425_CR10","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri, G. et al. mRNA vaccine\u2013induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Invest. 130, 5976\u20135988 (2020).","journal-title":"J. Clin. Invest."},{"key":"1425_CR11","doi-asserted-by":"crossref","unstructured":"Liu, M. A., Zhou, T., Sheets, R. L., Meyer, H. & Knezevic, I. WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20\u201322 April 2021. Emerg. Microbes Infect. 11, 384\u2013391.","DOI":"10.1080\/22221751.2022.2026742"},{"key":"1425_CR12","unstructured":"Research, C. For B. E. and. Clinical Considerations for Therapeutic Cancer Vaccines. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-considerations-therapeutic-cancer-vaccines (2019)."},{"key":"1425_CR13","unstructured":"Development of a guideline on the quality aspects of mRNA vaccines - Scientific guideline | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/development-guideline-quality-aspects-mrna-vaccines-scientific-guideline (2023)."},{"key":"1425_CR14","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","volume":"12","author":"Q He","year":"2022","unstructured":"He, Q., Gao, H., Tan, D., Zhang, H. & Wang, J. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm. Sin. B 12, 2969\u20132989 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","volume":"15","author":"N Al Fayez","year":"2023","unstructured":"Al Fayez, N. et al. Recent Advancement in mRNA Vaccine Development and Applications. Pharmaceutics 15, 1972 (2023).","journal-title":"Pharmaceutics"},{"key":"1425_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1134\/S0006297921070014","volume":"86","author":"EV Semina","year":"2021","unstructured":"Semina, E. V., Rysenkova, K. D., Troyanovskiy, K. E., Shmakova, A. A. & Rubina, K. A. MicroRNAs in cancer: From gene expression regulation to the metastatic niche reprogramming. Biochem. Mosc. 86, 785\u2013799 (2021).","journal-title":"Biochem. Mosc."},{"key":"1425_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2021.04.013","volume":"124","author":"SN Lone","year":"2022","unstructured":"Lone, S. N. et al. miRNAs as novel immunoregulators in cancer. Semin. Cell Dev. Biol. 124, 3\u201314 (2022).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1425_CR18","first-page":"1","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng, Y. & Croce, C. M. The role of MicroRNAs in human cancer. Signal Transduct. Target. Ther. 1, 1\u20139 (2016).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1425_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.omtn.2020.03.003","volume":"20","author":"D Bautista-S\u00e1nchez","year":"2020","unstructured":"Bautista-S\u00e1nchez, D. et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol. Ther. Nucleic Acids 20, 409\u2013420 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1425_CR20","doi-asserted-by":"publisher","first-page":"110903","DOI":"10.1016\/j.biopha.2020.110903","volume":"132","author":"A Safa","year":"2020","unstructured":"Safa, A. et al. miR-1: A comprehensive review of its role in normal development and diverse disorders. Biomed. Pharmacother. 132, 110903 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1425_CR21","doi-asserted-by":"crossref","unstructured":"Johansson, K. et al. An essential role for miR-15\/16 in Treg suppression and restriction of proliferation. Cell Rep. 42, 1\u201313 (2023).","DOI":"10.2139\/ssrn.4441801"},{"key":"1425_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2013.09.105","volume":"533","author":"X Li","year":"2014","unstructured":"Li, X. miR-375, a microRNA related to diabetes. Gene 533, 1\u20134 (2014).","journal-title":"Gene"},{"key":"1425_CR23","doi-asserted-by":"crossref","unstructured":"Detassis, S., Grasso, M., Del Vescovo, V. & Denti, M. A. microRNAs make the call in cancer personalized medicine. Front. Cell Dev. Biol. 5, 1\u20139 (2017).","DOI":"10.3389\/fcell.2017.00086"},{"key":"1425_CR24","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin, G. A. et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 99, 15524\u201315529 (2002).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1425_CR25","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","volume":"65","author":"MV Iorio","year":"2005","unstructured":"Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065\u20137070 (2005).","journal-title":"Cancer Res."},{"key":"1425_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40291-020-00447-w","volume":"24","author":"V Aggarwal","year":"2020","unstructured":"Aggarwal, V., Priyanka, K. & Tuli, H. S. Emergence of circulating MicroRNAs in breast cancer as diagnostic and therapeutic efficacy biomarkers. Mol. Diagn. Ther. 24, 153\u2013173 (2020).","journal-title":"Mol. Diagn. Ther."},{"key":"1425_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-024-01634-1","volume":"24","author":"X Luo","year":"2024","unstructured":"Luo, X. & Wen, W. MicroRNA in prostate cancer: From biogenesis to applicative potential. BMC Urol. 24, 244 (2024).","journal-title":"BMC Urol."},{"key":"1425_CR28","doi-asserted-by":"crossref","unstructured":"Detassis, S. et al. miR375-3p distinguishes low-grade neuroendocrine from non-neuroendocrine lung tumors in FFPE samples. Front. Mol. Biosci. 7, 1\u201311 (2020).","DOI":"10.3389\/fmolb.2020.00086"},{"key":"1425_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41420-023-01499-7","volume":"9","author":"J Gan","year":"2023","unstructured":"Gan, J. et al. MicroRNA-375 restrains the progression of lung squamous cell carcinoma by modulating the ERK pathway via UBE3A-mediated DUSP1 degradation. Cell Death Discov. 9, 199 (2023).","journal-title":"Cell Death Discov."},{"key":"1425_CR30","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1158\/0008-5472.CAN-11-1020","volume":"71","author":"E Nishikawa","year":"2011","unstructured":"Nishikawa, E. et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res. 71, 6165\u20136173 (2011).","journal-title":"Cancer Res."},{"key":"1425_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/andr.12595","volume":"7","author":"WPA Boellaard","year":"2019","unstructured":"Boellaard, W. P. A. et al. Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation. Andrology 7, 463\u2013468 (2019).","journal-title":"Andrology"},{"key":"1425_CR32","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41416-023-02453-1","volume":"129","author":"S Bailey","year":"2023","unstructured":"Bailey, S. et al. Targeting oncogenic microRNAs from the miR-371~373 and miR-302\/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption. Br. J. Cancer 129, 1451\u20131461 (2023).","journal-title":"Br. J. Cancer"},{"key":"1425_CR33","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jcmm.14013","volume":"23","author":"M Mego","year":"2019","unstructured":"Mego, M. et al. Clinical utility of plasma miR-371a-3p in germ cell tumors. J. Cell. Mol. Med. 23, 1128\u20131136 (2019).","journal-title":"J. Cell. Mol. Med."},{"key":"1425_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","volume":"183","author":"AG Seto","year":"2018","unstructured":"Seto, A. G. et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 183, 428\u2013444 (2018).","journal-title":"Br. J. Haematol."},{"key":"1425_CR35","unstructured":"FDA Grants Orphan Designation to Cobomarsen for T-Cell Lymphomas. Targeted Oncology https:\/\/www.targetedonc.com\/view\/fda-grants-orphan-designation-to-cobomarsen-for-t-cell-lymphomas (2020)."},{"key":"1425_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg, M. S. et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest. N. Drugs 35, 180\u2013188 (2017).","journal-title":"Invest. N. Drugs"},{"key":"1425_CR37","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1002\/jcp.28058","volume":"234","author":"H Mollaei","year":"2019","unstructured":"Mollaei, H., Safaralizadeh, R. & Rostami, Z. MicroRNA replacement therapy in cancer. J. Cell. Physiol. 234, 12369\u201312384 (2019).","journal-title":"J. Cell. Physiol."},{"key":"1425_CR38","doi-asserted-by":"publisher","first-page":"e1662","DOI":"10.1002\/wrna.1662","volume":"12","author":"LF Sempere","year":"2021","unstructured":"Sempere, L. F., Azmi, A. S. & Moore, A. microRNA-based diagnostic and therapeutic applications in cancer medicine. WIREs RNA 12, e1662 (2021).","journal-title":"WIREs RNA"},{"key":"1425_CR39","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N Van Zandwijk","year":"2017","unstructured":"Van Zandwijk, N. et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 18, 1386\u20131396 (2017).","journal-title":"Lancet Oncol."},{"key":"1425_CR40","unstructured":"Asbestos Diseases Research Foundation. MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy. https:\/\/clinicaltrials.gov\/study\/NCT02369198 (2017)."},{"key":"1425_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.humpath.2020.10.007","volume":"107","author":"CE Freitag","year":"2021","unstructured":"Freitag, C. E., Mei, P., Wei, L., Parwani, A. V. & Li, Z. ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience. Hum. Pathol. 107, 80\u201386 (2021).","journal-title":"Hum. Pathol."},{"key":"1425_CR42","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1210\/me.2007-0022","volume":"21","author":"BD Adams","year":"2007","unstructured":"Adams, B. D., Furneaux, H. & White, B. A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. Baltim. Md 21, 1132\u20131147 (2007).","journal-title":"Mol. Endocrinol. Baltim. Md"},{"key":"1425_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jcph.1553","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Goel, V. & Robbie, G. J. Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis. J. Clin. Pharmacol. 60, 573\u2013585 (2020).","journal-title":"J. Clin. Pharmacol."},{"key":"1425_CR44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1425_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ncrna9020027","volume":"9","author":"E Bayraktar","year":"2023","unstructured":"Bayraktar, E. et al. Targeting miRNAs and other non-coding RNAs as a therapeutic approach: An update. Non-Coding RNA 9, 27 (2023).","journal-title":"Non-Coding RNA"},{"key":"1425_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2104511118","volume":"118","author":"J Lee","year":"2021","unstructured":"Lee, J., Sands, I., Zhang, W., Zhou, L. & Chen, Y. DNA-inspired nanomaterials for enhanced endosomal escape. Proc. Natl. Acad. Sci. 118, e2104511118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"1425_CR47","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","volume":"75","author":"B Wightman","year":"1993","unstructured":"Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855\u2013862 (1993).","journal-title":"Cell"},{"key":"1425_CR48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","volume":"75","author":"RC Lee","year":"1993","unstructured":"Lee, R. C., Feinbaum, R. L. & Ambros, V. T. heC. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843\u2013854 (1993).","journal-title":"Cell"},{"key":"1425_CR49","unstructured":"The Nobel Prize in Physiology or Medicine 2024. NobelPrize.org https:\/\/www.nobelprize.org\/prizes\/medicine\/2024\/press-release\/."},{"key":"1425_CR50","doi-asserted-by":"publisher","unstructured":"What will it take to get miRNA therapies to market? Nat. Biotechnol. 42, 1623\u20131624. https:\/\/doi.org\/10.1038\/s41587-024-02480-0 (2024).","DOI":"10.1038\/s41587-024-02480-0"},{"key":"1425_CR51","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tig.2019.09.006","volume":"35","author":"H Lee","year":"2019","unstructured":"Lee, H., Zhang, Z. & Krause, H. M. Long noncoding RNAs and repetitive elements: Junk or intimate evolutionary partners? Trends Genet 35, 892\u2013902 (2019).","journal-title":"Trends Genet"},{"key":"1425_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino, M. T. D., Tagliaferri, P. & Tassone, P. MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications. J. Exp. Clin. Cancer Res. 44, 126 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1425_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203\u2013222 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1425_CR54","doi-asserted-by":"publisher","first-page":"851","DOI":"10.15252\/emmm.201100899","volume":"6","author":"E van Rooij","year":"2014","unstructured":"van Rooij, E. & Kauppinen, S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 6, 851\u2013864 (2014).","journal-title":"EMBO Mol. Med."},{"key":"1425_CR55","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/ijms22031176","volume":"22","author":"F Precazzini","year":"2021","unstructured":"Precazzini, F., Detassis, S., Imperatori, A. S., Denti, M. A. & Campomenosi, P. Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis. Int. J. Mol. Sci. 22, 1176 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1425_CR56","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1021\/acs.analchem.8b05909","volume":"91","author":"T Ouyang","year":"2019","unstructured":"Ouyang, T., Liu, Z., Han, Z. & Ge, Q. MicroRNA Detection Specificity: Recent Advances and Future Perspective. Anal. Chem. 91, 3179\u20133186 (2019).","journal-title":"Anal. Chem."},{"key":"1425_CR57","doi-asserted-by":"crossref","unstructured":"Zschaler, J., Schlorke, D. & Arnhold, J. Differences in Innate Immune Response between Man and Mouse. Crit. Rev. Immunol. 34, 433\u2013454 (2014).","DOI":"10.1615\/CritRevImmunol.2014011600"},{"key":"1425_CR58","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Shi, M., Wang, Y. & You, J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct. Target. Ther. 9, 322 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1425_CR59","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics \u2014 challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629\u2013651 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1425_CR60","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1425_CR61","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","volume":"63","author":"PE Saw","year":"2020","unstructured":"Saw, P. E. & Song, E.-W. siRNA therapeutics: A clinical reality. Sci. China Life Sci. 63, 485\u2013500 (2020).","journal-title":"Sci. China Life Sci."},{"key":"1425_CR62","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.3390\/cells10113097","volume":"10","author":"MY Momin","year":"2021","unstructured":"Momin, M. Y., Gaddam, R. R., Kravitz, M., Gupta, A. & Vikram, A. The challenges and opportunities in the development of MicroRNA therapeutics: A multidisciplinary viewpoint. Cells 10, 3097 (2021).","journal-title":"Cells"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01425-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:04:04Z","timestamp":1779062644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01425-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01425-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}